Literature DB >> 16361251

SUMO-3 enhances androgen receptor transcriptional activity through a sumoylation-independent mechanism in prostate cancer cells.

Zhe Zheng1, Changmeng Cai, Josephat Omwancha, Shao-Yong Chen, Timour Baslan, Lirim Shemshedini.   

Abstract

Androgens are important for male sexual development, which depend on the cognate receptor, the androgen receptor. The transcriptional activity of the androgen receptor, like other nuclear receptors, is regulated by accessory proteins that can have either positive or negative effects. Through a yeast functional screen, we have identified SUMO-3 as a regulator of androgen receptor activity in prostate cancer cells. SUMO-3 is one of three eukaryotic proteins that become post-translationally conjugated to their target proteins in a manner analogous to the attachment of ubiquitin. In primary prostate epithelial cells, PrEC, and the prostate cancer cells, PC-3, SUMO-3 has a weak negative effect on androgen receptor transcriptional activity. In contrast, SUMO-3 and it close relative SUMO-2 strongly enhance transactivation by endogenous androgen receptor in LNCaP cells. This positive effect is observed in both androgen-dependent and androgen-independent LNCaP cells. Interestingly, SUMO-1, unlike SUMO-3 and SUMO-2, can inhibit, but not stimulate, androgen receptor activity. Mutational analysis of the androgen receptor and SUMO-3 demonstrates that the SUMO-3-positive activity does not depend on either the sumoylation sites of the androgen receptor or the sumoylation function of SUMO-3. Stable overexpression of SUMO-3 in LNCaP cells significantly enhances the androgen-dependent proliferation of these cells. Additionally, siRNA-mediated repression of SUMO-2 significantly inhibits the growth of both androgen-dependent and -independent LNCaP cells. Collectively, these results suggest (i) a novel mechanism for elevating AR activity through the switch of SUMO-3 from a weak negative regulator in normal prostate cells to a strong positive regulator in prostate cancer cells and (ii) a proliferative role for SUMO-3 and SUMO-2 in the growth of prostate cancer cells that is independent of sumoylation of the androgen receptor.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16361251     DOI: 10.1074/jbc.M509260200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  19 in total

1.  Paxillin regulates androgen- and epidermal growth factor-induced MAPK signaling and cell proliferation in prostate cancer cells.

Authors:  Aritro Sen; Katherine O'Malley; Zhou Wang; Ganesh V Raj; Donald B Defranco; Stephen R Hammes
Journal:  J Biol Chem       Date:  2010-07-13       Impact factor: 5.157

2.  Gold nanoparticles as a platform for creating a multivalent poly-SUMO chain inhibitor that also augments ionizing radiation.

Authors:  Yi-Jia Li; Angela L Perkins; Yang Su; Yuelong Ma; Loren Colson; David A Horne; Yuan Chen
Journal:  Proc Natl Acad Sci U S A       Date:  2012-03-02       Impact factor: 11.205

3.  Small ubiquitin-like modifier (SUMO) isoforms and conjugation-independent function in DNA double-strand break repair pathways.

Authors:  Yiheng Hu; Jeffrey D Parvin
Journal:  J Biol Chem       Date:  2014-06-25       Impact factor: 5.157

Review 4.  Mouse models of Down syndrome: gene content and consequences.

Authors:  Meenal Gupta; A Ranjitha Dhanasekaran; Katheleen J Gardiner
Journal:  Mamm Genome       Date:  2016-08-18       Impact factor: 2.957

Review 5.  Nuclear Receptor Coregulators in Hormone-Dependent Cancers.

Authors:  Hedieh Jafari; Shahid Hussain; Moray J Campbell
Journal:  Cancers (Basel)       Date:  2022-05-13       Impact factor: 6.575

6.  Small ubiquitin-like modifier (SUMO) modification of the androgen receptor attenuates polyglutamine-mediated aggregation.

Authors:  Sarmistha Mukherjee; Monzy Thomas; Nahid Dadgar; Andrew P Lieberman; Jorge A Iñiguez-Lluhí
Journal:  J Biol Chem       Date:  2009-06-04       Impact factor: 5.157

7.  Genome-wide impact of androgen receptor trapped clone-27 loss on androgen-regulated transcription in prostate cancer cells.

Authors:  Jerome C Nwachukwu; Paolo Mita; Rachel Ruoff; Susan Ha; Qianben Wang; S Joseph Huang; Samir S Taneja; Myles Brown; William L Gerald; Michael J Garabedian; Susan K Logan
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

8.  Protein inhibitors of activated STAT (Pias1 and Piasy) differentially regulate pituitary homeobox 2 (PITX2) transcriptional activity.

Authors:  Jianbo Wang; Zhao Sun; Zichao Zhang; Irfan Saadi; Jun Wang; Xiao Li; Shan Gao; Jamison J Engle; Adisa Kuburas; Xueyao Fu; Wenjie Yu; William H Klein; Andrew F Russo; Brad A Amendt
Journal:  J Biol Chem       Date:  2013-03-20       Impact factor: 5.157

9.  Modulation of Abeta generation by small ubiquitin-like modifiers does not require conjugation to target proteins.

Authors:  Véronique Dorval; Matthew J Mazzella; Paul M Mathews; Ronald T Hay; Paul E Fraser
Journal:  Biochem J       Date:  2007-06-01       Impact factor: 3.857

Review 10.  Post-Translational Modifications That Drive Prostate Cancer Progression.

Authors:  Ivana Samaržija
Journal:  Biomolecules       Date:  2021-02-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.